Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma

被引：3

作者：

Harrison, Douglas ^{[1
]}

Gill, Jonathan ^{[1
]}

Roth, Michael ^{[1
]}

Hingorani, Pooja ^{[1
]}

Zhang, Wendong ^{[1
]}

Teicher, Beverly ^{[2
]}

Earley, Eric ^{[3
]}

Erickson, Stephen ^{[3
]}

Gatto, Gregory ^{[3
]}

Kumasheva, Raushan ^{[4
]}

Houghton, Peter ^{[4
]}

Smith, Malcolm ^{[2
]}

Kolb, E. Anders ^{[5
]}

Gorlick, Richard ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA

[2] NCI, Canc Therapeut Evaluat Program, Bethesda, MD 20892 USA

[3] RTI Int, Global Hlth Technol, Res Triangle Pk, NC USA

[4] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA

[5] Nemours Alfred I DuPont Hosp Children, Div Pediat Hematol Oncol, Wilmington, DE USA

来源：

PEDIATRIC BLOOD & CANCER | 2023年 / 70卷 / 01期

关键词：

MTOR KINASE INHIBITOR; ONCOLOGY-GROUP; STAGE; THERAPY; MLN0128; PATHWAY; CANCER;

D O I：

10.1002/pbc.30017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, with activity against all four PI3K class I isoforms (PI3K alpha, PI3K beta, PI3K gamma, and PI3K delta). Whole-genome and RNA sequencing data have revealed several PI3K aberrations in osteosarcoma tumor samples. The in vivo anticancer effects of copanlisib were assessed in a panel of six osteosarcoma models. Copanlisib induced prolonged event-free survival in five of six osteosarcoma models; however, all models demonstrated progressive disease suggesting minimal activity. While copanlisib did not result in tumor regression, more data are needed to fully explore the role of the PI3K pathway in the pathogenesis of osteosarcoma.

引用

页数：5

共 20 条

[1] Initial Testing (Stage 1) of the Akt Inhibitor GSK690693 by the Pediatric Preclinical Testing Program [J].

Carol, Hernan ;

Morton, Christopher L. ;

Gorlick, Richard ;

Kolb, E. Anders ;

Keir, Stephen T. ;

Reynolds, C. Patrick ;

Kang, Min H. ;

Maris, John M. ;

Billups, Catherine ;

Smith, Malcolm A. ;

Houghton, Peter J. ;

Lock, Richard B. .

PEDIATRIC BLOOD & CANCER, 2010, 55 (07) :1329-1337

[2] Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F [J].

Damodaran, Senthil ;

Zhao, Fengmin ;

Deming, Dustin A. ;

Mitchell, Edith P. ;

Wright, John J. ;

Gray, Robert J. ;

Wang, Victoria ;

McShane, Lisa M. ;

Rubinstein, Larry, V ;

Patton, David R. ;

Williams, P. Mickey ;

Hamilton, Stanley R. ;

Suga, Jennifer M. ;

Conley, Barbara A. ;

Arteaga, Carlos L. ;

Harris, Lyndsay N. ;

O'Dwyer, Peter J. ;

Chen, Alice P. ;

Flaherty, Keith T. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (14) :1552-+

[3] BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma [J].

Gobin, Berengere ;

Baud'Huin, Marc ;

Lamoureux, Francois ;

Ory, Benjamin ;

Charrier, Celine ;

Lanel, Rachel ;

Battaglia, Severine ;

Redini, Francoise ;

Lezot, Frederic ;

Blanchard, Frederic ;

Heymann, Dominique .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (04) :784-796

[4] NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate [J].

Gobin, Berengere ;

Battaglia, Seyerine ;

Lanel, Rachel ;

Chesneau, Julie ;

Amiaud, Jerome ;

Redini, Francoise ;

Ory, Benjamin ;

Heymann, Dominique .

CANCER LETTERS, 2014, 344 (02) :291-298

[5] Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group trial [J].

Goorin, AM ;

Harris, MB ;

Bernstein, M ;

Ferguson, W ;

Devidas, M ;

Siegal, GP ;

Gebhardt, MC ;

Schwartz, CL ;

Link, M ;

Grier, HE .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :426-433

[6] Current and future therapeutic approaches for osteosarcoma [J].

Harrison, Douglas J. ;

Geller, David S. ;

Gill, Jonathan D. ;

Lewis, Valerae O. ;

Gorlick, Richard .

EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) :39-50

[7] Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program [J].

Houghton, Peter J. ;

Morton, Christopher L. ;

Kolb, E. Anders ;

Gorlick, Richard ;

Lock, Richard ;

Carol, Hernan ;

Reynolds, C. Patrick ;

Maris, John M. ;

Keir, Stephen T. ;

Billups, Catherine A. ;

Smith, Malcolm A. .

PEDIATRIC BLOOD & CANCER, 2008, 50 (04) :799-805

[8] Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program [J].

Houghton, Peter J. ;

Gorlick, Richard ;

Kolb, E. Anders ;

Lock, Richard ;

Carol, Hernan ;

Morton, Christopher L. ;

Keir, Stephen T. ;

Reynolds, C. Patrick ;

Kang, Min H. ;

Phelps, Doris ;

Maris, John M. ;

Billups, Catherine ;

Smith, Malcolm A. .

PEDIATRIC BLOOD & CANCER, 2012, 58 (02) :191-199

[9]

Ingham M, 2020, J CLIN ONCOL, V38

[10] Targeting the PI3K pathway in cancer: are we making headway? [J].

Janku, Filip ;

Yap, Timothy A. ;

Meric-Bernstam, Funda .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (05) :273-291

← 1 2 →